7 Top Stocks Under $10: June 2024 Edition
While blue chip stocks are always a good investment portfolio idea, I suggest some smart diversification. And one of the best ways that I know to diversify is to buy highly rated stocks under $10. St...
- Supported exchanges /
- NASDAQ /
- ANNX.NASDAQ
Annexon Inc (ANNX NASDAQ) stock market data APIs
$7.48
-0.09(-1.2%)
as of October 22, 2024
Price chart is built with Anychart
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Annexon Inc Financial Data Overview
| 7.57 | |
| 7.48 | |
| - | |
| 7.74 | |
| 7.47 | |
| 1.9-8.4 | |
| 800 M | |
| 106 M | |
| 0 | |
| -0.23 | |
| 1.279 |
Our easy-to-use no-coding solutions help you get the data effortlessly:
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
General: {
Code:
'ANNX',
Type:
'Common Stock',
Name:
'Annexon Inc',
Exchange:
'NASDAQ',
CurrencyCode:
'USD',
CurrencyName:
'US Dollar',
CurrencySymbol:
'$',
CountryName:
'USA',
CountryISO:
'US',
OpenFigi:
'BBG007QVDFG2',
ISIN:
NULL,
CUSIP:
NULL,
CIK:
'1528115',
EmployerIdNumber:
NULL,
FiscalYearEnd:
'December',
IPODate:
'2020-07-24',
InternationalDomestic:
NULL,
Sector:
'Healthcare',
Industry:
'Biotechnology',
HomeCategory:
NULL,
IsDelisted:
false,
}
Annexon Inc Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA -124 791 000
- Earnings Per Share -1.21
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Annexon Inc Earnings via APIs
- Latest Release 2024-08-12
- EPS/Forecast -0.23
Get Annexon Inc End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Get Annexon Inc latest news via APIs
Turnstone Biologics Appoints William Waddill to its Board of Directors
Turnstone Biologics Corp. SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company develop...
Do you have any questions?
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
